Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and Sprague-Dawley rats: Implications of decreased glucuronidation in obese Zucker rats

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 909-914

  Kim, Mi Sook ^a   Wang, Sui ^a   Shen, Zhongzhou ^a   Kochansky, Christopher J ^a   Strauss, John R ^a   Franklin, Ronald B ^a   Vincent, Stella H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [2 CHLORO 4 (2,2,2 TRIFLUOROETHOXY)PHENOXY]PROPOXY] 3,4 DIHYDRO 2 METHYL 2H BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 CHLORO 4 (4 FLUOROPHENOXY)PHENOXY]PROPOXY] 2 ETHYL 3,4 DIHYDRO 2H BENZOPYRAN 2 CARBOXYLIC ACID; CARBON 14; CYTOCHROME P450 2C11; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B1; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; GENETIC MODEL; IN VITRO STUDY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN;

ANIMALS; BENZOPYRANS; BILE; BLOOD PROTEINS; CARBON RADIOISOTOPES; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; ORGANIC ANION TRANSPORTERS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RNA, MESSENGER; SPECIES SPECIFICITY; XENOBIOTICS;

ANIMALIA;

EID: 4143079604     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, and Yawo H (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and tautocholate and comparison with oatp2. J Biol Chem 272:22395-22401.
2. Abernethy DR and Greenblatt DJ (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 7:108-124.
3. Benedek IH, Blouin RA, and McNamara PJ (1984) Serum protein binding and the role of increased α1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941-946.
4. Benedek IH, Blouin R, and McNamara PJ (1985) Altered drug-serum protein binding in the genetically obese Zucker rat. J Pharm Sci 74:837-840.
5. Berger J and Moller D (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
6. Bray GA (1977) The Zucker-fatty rat: a review. Fed Proc 36:148-153.
7. Brouwer KLR, Kostenbauder HB, McNamara PJ, and Blouin RA (1984) Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther 231:649-653.
8. Campfield LA, Smith FJ, and Burn P (1996) The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm Metab Res 28:619-632.
9. Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, and Blouin RA (1993) Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways. J Pharmacol Exp Ther 265:1333-1338.
10. Cherrington NJ, Hartley DP, Li N, Johnson DR, and Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2 and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
11. Colburn WA and Gibaldi M (1978) Prolonged impairment of the plasma-protein binding of phenytoin in the rat after a single dose of sodium oleate. Drug Metab Dispos 6:452-455.
12. Considine RV (1996) Weight regulation, leptin and growth hormone. Horm Res 48:116-121.
13. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier P, and Hagenbuch B (1999) Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol 272:G1037-G1042.
14. Enriquez A, Leclercq I, Farrell GC, and Robertson G (1999) Altered expression of hepatic CYP2EI and CYP4A in obese, diabetic ob/ob mice and fa/fa Zucker rats. Biochem Biophys Res Commun 155:300-306.
15. Galinsky RE, Kane RE, and Franklin MR (1986) Effect of aging on drug-metabolizing enzymes important in acetaminophen elimination. J Pharmacol Exp Ther 237:107-113.
16. Gerk PM and Vote M (2002) Regulation of expression of the multidrug resistance associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 302:407-415.
17. Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (MRP3). J Biol Chem 274:15181-15185.
18. Jansen PL, Peters WH, and Lamers WH (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 5:573-579.
19. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease. Nature (Lond) 405:421-423.
20. Kim MS, Liu DQ, Strauss JR, Capodanno I, Yao Z, Fenyk-Melody JE, Franklin RB, and Vincent SH (2003) Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR-rats. Xenobiotica 33:1027-1042.
21. Kim MS, Shen Z, Kochansky CJ, Lynn K, Wang S, Wang Z, Hora D, Brunner J, Franklin RB. and Vincent SH (2004) Differences in the metabolism and pharmacokinetics of two structurally similar PPAR agonists in dogs: involvement of taurine conjugation. Xenobiotica, in press.
22. Koyama H, Miller DJ, Boueres J, Desai RC, Jones AB, Berger JP, MacNaul KL, Kelly LI, Doebber TW, Wu MS, et al. (2004) (2R)-2-Ethylchromane-2-carboxylic acids: discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents. J Med Chem 47:3255-3263.
23. Krief S and Bazin R (1991) Genetic obesity: is the defect in the sympathetic nervous system? A review through developmental studies in the preobese Zucker rat. Proc Soc Exp Biol Med 198:528-538.
24. Kurtz TW, Morris RC, and Pershadsingh HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13:896-901.
25. Litterst CL (1980) In vitro hepatic dug metabolism and microsomal enzyme induction in genetically obese rats. Biochem Pharmacol 29:289-296.
26. Noe B, Hagenbach B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
27. Oude Elferink RPJ and Jansen PLM (1994) The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol Ther 64:77-97.
28. Porter RJ and Layzer RB (1975) Plasma albumin concentration and diphenylhydantoin binding in man. Arch Neurol 32:298-303.
29. Raucy JL and Lasker JM (1991) Purification of P450 enzymes from human liver, in Methods in Enzymology: Cytochrome P450, (John EF and Waterman MR eds) pp 577-587, Academic Press, Inc., San Diego.
30. Renes J, de Vries EG, Jansen PL, and Müller M (2000) The (patho)physiological functions of the MRP family. Drug Resist Update 3:289-302.
31. Roe AL, Howard G, Blouin R, and Snawder JE (1999) Characterization of cytochrome P450 and glutathione S-transferase activity and expression in male and female ob/ob mice. Int J Obes Relat Metab Disord 23:48-53.
32. Schoonjans K, Staels B, and Auwerx J (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109.
33. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, and Schinkel AH (2000) Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57:188-197.
34. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
35. Stevenson FT and Kaysen GA (1999) Hyperlipidemia and renal disease: the use of animal models in understanding pathology and approaches to treatment. Wien Klin Wochenschr 111:307-414.
36. Wahli W, Braissant O, and Desvergne B (1995) Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 2:261-266.
37. Wang S, Hartley DP, Ciccotto SL, Vincent SH, Franklin RB, and Kim M-S (2003) Induction of the hepatic phase II drug metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of Mrp3. Drug Metab Dispos 31:773-775.
38. Wong BK, Ernest S-W, and Corcoran GG (1986) An overfed rat model that reproduces acetaminophen disposition in obese humans. Drug Metab Dispos 14:674-679.
39. Zucker TF and Zucker LM (1961) Fatty, a new mutation in the rat. J Hered 52:275-278.